Loading…

Treatment of the antiphospholipid syndrome

The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent rec...

Full description

Saved in:
Bibliographic Details
Published in:Autoimmunity highlights 2014-06, Vol.5 (1), p.1-7
Main Author: Galli, Monica
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63
cites cdi_FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63
container_end_page 7
container_issue 1
container_start_page 1
container_title Autoimmunity highlights
container_volume 5
creator Galli, Monica
description The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.
doi_str_mv 10.1007/s13317-013-0056-5
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4389011</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2404294630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63</originalsourceid><addsrcrecordid>eNpdUVtLwzAYDaI4mfsBvkjBFxGqX65NXwQZ3mDgy3wOaZq6jrapSSvs35uxOdRASMI55-OcHIQuMNxigOwuYEpxlgKmKQAXKT9CZwSoTCnJ2PH-DhT4BM1CWENcNI8QnKIJEfGFOZyhm6W3emhtNySuSoaVTXQ31P3Khbibuq_LJGy60rvWnqOTSjfBzvbnFL0_PS7nL-ni7fl1_rBIDeNkSDWnuuKaZaQEo3FRYBoByYRguaiIMbSwIou2rcYGa8otK7Mo4iArwitBp-h-N7cfi9aWJnrzulG9r1vtN8rpWv1FunqlPtyXYlTmgHEccL0f4N3naMOg2joY2zS6s24MCgtJpJRMZpF69Y-6dqPvYjxFGDCSM0EhsvCOZbwLwdvqYAaD2pahdmWomEpty1A8ai5_pzgofr6efgNFTIPJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2404294630</pqid></control><display><type>article</type><title>Treatment of the antiphospholipid syndrome</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Galli, Monica</creator><creatorcontrib>Galli, Monica</creatorcontrib><description>The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.</description><identifier>ISSN: 2038-0305</identifier><identifier>EISSN: 2038-3274</identifier><identifier>DOI: 10.1007/s13317-013-0056-5</identifier><identifier>PMID: 26000150</identifier><language>eng</language><publisher>England: Springer Nature B.V</publisher><subject>Antiphospholipid antibodies ; Antiphospholipid syndrome ; Aspirin ; Autografts ; Corticosteroids ; Heparin ; Hydroxychloroquine ; Molecular weight ; Monoclonal antibodies ; Review ; Rituximab ; Stem cell transplantation ; Thrombosis</subject><ispartof>Autoimmunity highlights, 2014-06, Vol.5 (1), p.1-7</ispartof><rights>Springer-Verlag Italia 2013.</rights><rights>Springer-Verlag Italia 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63</citedby><cites>FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389011/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2404294630?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26000150$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galli, Monica</creatorcontrib><title>Treatment of the antiphospholipid syndrome</title><title>Autoimmunity highlights</title><addtitle>Auto Immun Highlights</addtitle><description>The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.</description><subject>Antiphospholipid antibodies</subject><subject>Antiphospholipid syndrome</subject><subject>Aspirin</subject><subject>Autografts</subject><subject>Corticosteroids</subject><subject>Heparin</subject><subject>Hydroxychloroquine</subject><subject>Molecular weight</subject><subject>Monoclonal antibodies</subject><subject>Review</subject><subject>Rituximab</subject><subject>Stem cell transplantation</subject><subject>Thrombosis</subject><issn>2038-0305</issn><issn>2038-3274</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdUVtLwzAYDaI4mfsBvkjBFxGqX65NXwQZ3mDgy3wOaZq6jrapSSvs35uxOdRASMI55-OcHIQuMNxigOwuYEpxlgKmKQAXKT9CZwSoTCnJ2PH-DhT4BM1CWENcNI8QnKIJEfGFOZyhm6W3emhtNySuSoaVTXQ31P3Khbibuq_LJGy60rvWnqOTSjfBzvbnFL0_PS7nL-ni7fl1_rBIDeNkSDWnuuKaZaQEo3FRYBoByYRguaiIMbSwIou2rcYGa8otK7Mo4iArwitBp-h-N7cfi9aWJnrzulG9r1vtN8rpWv1FunqlPtyXYlTmgHEccL0f4N3naMOg2joY2zS6s24MCgtJpJRMZpF69Y-6dqPvYjxFGDCSM0EhsvCOZbwLwdvqYAaD2pahdmWomEpty1A8ai5_pzgofr6efgNFTIPJ</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Galli, Monica</creator><general>Springer Nature B.V</general><general>Springer International Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140601</creationdate><title>Treatment of the antiphospholipid syndrome</title><author>Galli, Monica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antiphospholipid antibodies</topic><topic>Antiphospholipid syndrome</topic><topic>Aspirin</topic><topic>Autografts</topic><topic>Corticosteroids</topic><topic>Heparin</topic><topic>Hydroxychloroquine</topic><topic>Molecular weight</topic><topic>Monoclonal antibodies</topic><topic>Review</topic><topic>Rituximab</topic><topic>Stem cell transplantation</topic><topic>Thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galli, Monica</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Biological Sciences</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Autoimmunity highlights</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galli, Monica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of the antiphospholipid syndrome</atitle><jtitle>Autoimmunity highlights</jtitle><addtitle>Auto Immun Highlights</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>5</volume><issue>1</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>2038-0305</issn><eissn>2038-3274</eissn><abstract>The antiphospholipid syndrome is characterized by a combination of laboratory findings (i.e., the presence of at least one antiphospholipid antibody) and clinical manifestations (arterial and/or venous thrombosis, obstetrical complications). Long-term oral anticoagulant is recommended to prevent recurrence of both arterial and venous thrombosis, whereas (low molecular weight) heparin plus aspirin is the treatment of choice to prevent further obstetrical complications. In the rare case of catastrophic antiphospholipid syndrome, heparin plus high-dose corticosteroids plus plasma exchange is associated with the highest recovery rate. Some new, non-antithrombotic-based treatments of antiphospholipid syndrome with rituximab, autologous stem cell transplantation, or hydroxychloroquine are also reviewed.</abstract><cop>England</cop><pub>Springer Nature B.V</pub><pmid>26000150</pmid><doi>10.1007/s13317-013-0056-5</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2038-0305
ispartof Autoimmunity highlights, 2014-06, Vol.5 (1), p.1-7
issn 2038-0305
2038-3274
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4389011
source Publicly Available Content Database; PubMed Central
subjects Antiphospholipid antibodies
Antiphospholipid syndrome
Aspirin
Autografts
Corticosteroids
Heparin
Hydroxychloroquine
Molecular weight
Monoclonal antibodies
Review
Rituximab
Stem cell transplantation
Thrombosis
title Treatment of the antiphospholipid syndrome
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A16%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20the%20antiphospholipid%20syndrome&rft.jtitle=Autoimmunity%20highlights&rft.au=Galli,%20Monica&rft.date=2014-06-01&rft.volume=5&rft.issue=1&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=2038-0305&rft.eissn=2038-3274&rft_id=info:doi/10.1007/s13317-013-0056-5&rft_dat=%3Cproquest_pubme%3E2404294630%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c452t-a53af5a472d0ca1bb13c458466496f2cc3be67013ea1c1a35e4d7a53508f25f63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2404294630&rft_id=info:pmid/26000150&rfr_iscdi=true